AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3097178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diazepam (0.58 mg X kg‐1, range 0.50‐0.71)
Number of subjects: 0
Study 3097178 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 0
Study 3097178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and rectal diazepam
Number of subjects: 0
Study 30238247 — intervention group
Group type: EXPERIMENTAL
Intervention: N3b1 patients (16-20 metastatic lymph nodes)
Number of subjects: 222
Study 30238247 — intervention group
Group type: COMPARATOR
Intervention: N3b2 patients (≥21 metastatic lymph nodes)
Number of subjects: 222
Study 30238247 — intervention group
Group type: COMPARATOR
Intervention: Palliative surgery group
Number of subjects: 222
Study 29605135 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodiesel exhaust exposure
Number of subjects: 14
Study 29605135 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study 27896908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer (1500 mg/day adjusted up to 7500 mg/day)
Number of subjects: 163
Study 27896908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 27896908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer
Number of subjects: 163
Study 25250612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 28
Study 25250612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 28
Study 25250612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (for patients >= 20 kg)
Number of subjects: 28
Study 25250612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 28
Study 22253199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sinu-Foam™ mixture (n = 18)
Number of subjects: 36
Study 22253199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Sinu-Foam™ alone, n = 18)
Number of subjects: 36
Study 20434606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (0.5mg once a day, with option to increase to 0.5mg twice a day)
Number of subjects: 12
Study 20434606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17512160 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu-GMCSF, 125 microg/m2
Number of subjects: 36
Study 17512160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17512160 — intervention group
Group type: COMPARATOR
Intervention: Both groups (GMCSF and Control)
Number of subjects: 36
Study 16283978 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique using a laryngoscope
Number of subjects: 30
Study 16283978 — intervention group
Group type: COMPARATOR
Intervention: Open saphenous vein harvest
Number of subjects: 30
Study 12514774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg orally twice daily
Number of subjects: 30
Study 12514774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg orally twice daily
Number of subjects: 30
Study 12514774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 250 mg orally twice daily
Number of subjects: 30
Study 12514774 — intervention group
Group type: COMPARATOR
Intervention: Matched oral placebo twice daily
Number of subjects: 30
Study 10333095 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-S (tremometer test adapted for the rifle in the standing position)
Number of subjects: 24
Study 10333095 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-P (visual reaction time test in the prone position)
Number of subjects: 24
Study 8961069 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril or captopril
Number of subjects: 30
Study 1761082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled release salbutamol 4 mg
Number of subjects: 8
Study 1761082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled release salbutamol 8 mg
Number of subjects: 8
Study 7108069 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BD), 0.05 mg three times daily, sprayed in each nostril
Number of subjects: 39
Study 7108069 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BD)
Number of subjects: 39
Study 7108069 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 39
Study 3905468 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once at night
Number of subjects: 65
Study 3905468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31712971 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 800 mg/day
Number of subjects: 49
Study 31712971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29032252 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating advanced bipolar device (ENSEAL G2)
Number of subjects: 140
Study 29032252 — intervention group
Group type: COMPARATOR
Intervention: Electrothermal bipolar vessel sealer (LigaSure)
Number of subjects: 140
Study 27741342 — intervention group
Group type: EXPERIMENTAL
Intervention: FMX‐102 1%
Number of subjects: 32
Study 27741342 — intervention group
Group type: EXPERIMENTAL
Intervention: FMX‐102 4%
Number of subjects: 32
Study 27741342 — intervention group
Group type: EXPERIMENTAL
Intervention: FMX‐102 1% and 4%
Number of subjects: 32
Study 25018015 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day JNJ-40929837 for 6 days followed by 50 mg/day on day 7
Number of subjects: 22
Study 25018015 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day montelukast for 6 days
Number of subjects: 22
Study 25018015 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study 22080400 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐based pencil push‐ups
Number of subjects: 218
Study 22080400 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐based computer vergence/accommodative therapy and pencil push‐ups
Number of subjects: 218
Study 22080400 — intervention group
Group type: EXPERIMENTAL
Intervention: office‐based vergence/accommodative therapy with home reinforcement
Number of subjects: 218
Study 22080400 — intervention group
Group type: COMPARATOR
Intervention: office‐based placebo therapy with home reinforcement
Number of subjects: 218
Study 22080400 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful outcome
Number of subjects: 218
Study 22080400 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved outcome
Number of subjects: 218
Study 21079217 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT (70 mg) daily for 2 years
Number of subjects: 114
Study 21079217 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel daily for 2 years
Number of subjects: 114
Study 18218905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO; sucrose) at 0.96 g.kg(‐1).h(‐1)
Number of subjects: 10
Study 18218905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) gels
Number of subjects: 10
Study 18218905 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO; sucrose)
Number of subjects: 10
Study 17081356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cell (BM‐MNCs) transplantation (5.0 +/- 0.7 x 10^7)
Number of subjects: 30
Study 17081356 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 30
Study 11435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-150 mg for 24 weeks
Number of subjects: 387
Study 11435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sertraline and exposure therapy
Number of subjects: 387
Study 11435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 387
Study 11435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 387
Study 11435264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 9926765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amoxicillin and metronidazole therapy as an adjunct to mechanical treatment
Number of subjects: 25
Study 9926765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical treatment and antibiotics
Number of subjects: 25
Study 9926765 — intervention group
Group type: COMPARATOR
Intervention: Mechanical treatment and placebo
Number of subjects: 25
Study 8054806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 3 mg/kg before protamine administration
Number of subjects: 34
Study 8054806 — intervention group
Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 34
Study 3127852 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cigarette cessation
Number of subjects: 0
Study 3127852 — intervention group
Group type: COMPARATOR
Intervention: 50% reduction of number of cigarettes
Number of subjects: 0
Study 3127852 — intervention group
Group type: COMPARATOR
Intervention: Reduction of nicotine yield of cigarettes
Number of subjects: 0
Study 29562080 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐session Bridges/Puentes family‐focused group intervention
Number of subjects: 516
Study 29562080 — intervention group
Group type: COMPARATOR
Intervention: Control workshop
Number of subjects: 516
Study 27258122 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLUS score
Number of subjects: 100
Study 27258122 — intervention group
Group type: EXPERIMENTAL
Intervention: 2h-BOLUS score
Number of subjects: 100
Study 27258122 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTAL-BOLUS score
Number of subjects: 100
Study 27258122 — intervention group
Group type: COMPARATOR
Intervention: Frequency of glucose monitoring
Number of subjects: 100
Study 25113524 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Experiences After Loss (HEAL)
Number of subjects: 84
Study 25113524 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 22155702 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 0
Study 22155702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19940276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically reduced soluble epoxide hydrolase activity (EPHX2 genotypes)
Number of subjects: 10000
Study 18535395 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline social ties and emotional support
Number of subjects: 272
Study 18535395 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 272
Study 18535395 — intervention group
Group type: EXPERIMENTAL
Intervention: Social ties
Number of subjects: 272
Study 18535395 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exposures
Number of subjects: 272
Study 16052104 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinase I (maximum 35 microg/kg)
Number of subjects: 167
Study 16052104 — intervention group
Group type: COMPARATOR
Intervention: Protamine (maximum 650 mg)
Number of subjects: 167
Study 12537671 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-idiotypic monoclonal antibodies (Ab2) 2H4 or 5D3 with aluminum hydroxide-precipitated, accompanying radiotherapy
Number of subjects: 19
Study 12537671 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 19
Study 10473030 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan and its metabolite
Number of subjects: 0
Study 7600887 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement every other two days
Number of subjects: 238
Study 7600887 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement each week
Number of subjects: 238
Study 7600887 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement every day
Number of subjects: 238
Study 1699764 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 or 300 mg b.i.d. or 200 mg t.i.d.
Number of subjects: 0
Study 1699764 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 0
Study 1699764 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg b.i.d. or 50 mg t.i.d.
Number of subjects: 0
Study 324503 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunixin (SCH 14714)
Number of subjects: 0
Study 324503 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 324503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 117015066
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 117015066
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 117015066
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (β-agonist)
Number of subjects: 117015066
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (β-blocker)
Number of subjects: 117015066
Study 31327127 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 117015066
Study 30400773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaire sent to GPs
Number of subjects: 1000
Study 26967719 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic taping
Number of subjects: 20
Study 26967719 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene sleeve
Number of subjects: 20
Study 26967719 — intervention group
Group type: COMPARATOR
Intervention: Soccer cleat without external support (untaped control)
Number of subjects: 20
Study 24447238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 3522
Study 24447238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study 22265360 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (risperidone 0.5 to 3.5 mg/day; n = 49)
Number of subjects: 124
Study 22265360 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus parent training (average of 11.4 PT sessions; n = 75)
Number of subjects: 124
Study 22265360 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus parent training (n = 75)
Number of subjects: 124
Study 20354007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rested condition
Number of subjects: 29
Study 20354007 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprived condition
Number of subjects: 29
Study 17686658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Epidural Infusion (CEI) at 10 mL/h
Number of subjects: 195
Study 17686658 — intervention group
Group type: EXPERIMENTAL
Intervention: CEI + Patient-Controlled Epidural Analgesia (PCEA) at 5 mL/h with demand dose of 5 mL every 20 minutes
Number of subjects: 195
Study 17686658 — intervention group
Group type: COMPARATOR
Intervention: Demand dose-only PCEA (5 mL every 15 minutes)
Number of subjects: 195
Study 16234430 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 16234430 — intervention group
Group type: COMPARATOR
Intervention: Observational study in Ontario population
Number of subjects: 0
Study 11889779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ketamine 2 ml
Number of subjects: 43
Study 11889779 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml
Number of subjects: 43
Study 10725769 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of inulin with 210 mg of calcium
Number of subjects: 15
Study 10725769 — intervention group
Group type: COMPARATOR
Intervention: No inulin with 210 mg of calcium
Number of subjects: 15
Study 8635177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion
Number of subjects: 50
Study 8635177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1963648 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT (0.33 g/kg glucose solution)
Number of subjects: 14
Study 1963648 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT2 (0.5 g/kg glucose solution)
Number of subjects: 14
Study 1963648 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT + A (during aminophylline infusion)
Number of subjects: 14
Study 1963648 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT3 (after hemodialysis)
Number of subjects: 14
Study 1963648 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (29 healthy volunteers)
Number of subjects: 14
Study 7005439 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 109
Study 7005439 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 109
Study 31031266 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning alone
Number of subjects: 217
Study 31031266 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning combined with simulation‐based training
Number of subjects: 217
Study 31031266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 217
Study 28193490 — intervention group
Group type: EXPERIMENTAL
Intervention: A+PAAC intervention (target ≥100min/week, average delivered 55min/week)
Number of subjects: 584
Study 28193490 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 584
Study 26618456 — intervention group
Group type: EXPERIMENTAL
Intervention: HYC-24L (Juvéderm Ultra XC, 24 mg/mL hyaluronic acid with 0.3% lidocaine)
Number of subjects: 213
Study 26618456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, delayed treatment)
Number of subjects: 213
Study 26618456 — intervention group
Group type: EXPERIMENTAL
Intervention: HYC-24L
Number of subjects: 213
Study 24867688 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based PSA testing
Number of subjects: 420043
Study 24867688 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 420043
Study 22638812 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting alcohol (n = 37)
Number of subjects: 75
Study 22638812 — intervention group
Group type: COMPARATOR
Intervention: Not expecting alcohol (n = 38)
Number of subjects: 75
Study 22638812 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive individuals expecting alcohol
Number of subjects: 75
Study 22638812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-impulsive individuals
Number of subjects: 75
Study 19773024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic treatment + cognitive therapy
Number of subjects: 204
Study 19773024 — intervention group
Group type: COMPARATOR
Intervention: Dietetic treatment + physical exercise
Number of subjects: 204
Study 17476558 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 513
Study 15675270 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 60
Study 15675270 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Intravenous Insulin Infusion (IVII)
Number of subjects: 60
Study 15675270 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 60
Study 11807310 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased condom use; prevention campaign for female sex workers
Number of subjects: 0
Study 9719744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraucan 26G spinal needle
Number of subjects: 106
Study 9719744 — intervention group
Group type: COMPARATOR
Intervention: Sprotte 24G spinal needle
Number of subjects: 106
Study 1302160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg daily
Number of subjects: 770
Study 1302160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 770
Study 1302160 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg daily
Number of subjects: 770
Study 1302160 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg + Lasix 20 mg daily
Number of subjects: 770
Study 1302160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with ramipril
Number of subjects: 770
Study 3823619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (500 mg t.i.d.)
Number of subjects: 30
Study 3823619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 30
Study 3823619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31542339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 2 mg aflibercept every 4 weeks (monthly)
Number of subjects: 40
Study 31542339 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal 2 mg aflibercept every 12 weeks (quarterly)
Number of subjects: 40
Study 31542339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 29624676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported periodontal screening questions (Yes/No answers)
Number of subjects: 4890
Study 25891210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day
Number of subjects: 14
Study 25891210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 14
Study 24716820 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin bolus advisor (EXP)
Number of subjects: 218
Study 24716820 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CNL)
Number of subjects: 218
Study 21827730 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir + PEG‐IFN + RBV for 12 weeks and 24 weeks respectively
Number of subjects: 189
Study 21827730 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir + PEG‐IFN + RBV
Number of subjects: 189
Study 20236381 — intervention group
Group type: EXPERIMENTAL
Intervention: PITA injections
Number of subjects: 35
Study 20236381 — intervention group
Group type: COMPARATOR
Intervention: No PITA injections (Control)
Number of subjects: 35
Study 17972053 — intervention group
Group type: COMPARATOR
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes in males
Number of subjects: 1589
Study 17972053 — intervention group
Group type: COMPARATOR
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes in females
Number of subjects: 1589
Study 17972053 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes (combined effect)
Number of subjects: 1589
Study 17972053 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergic effects of GNB3/1429TT and LRP5/1330VV or AV
Number of subjects: 1589